Open Monoclonal Technology (OMT) partners with Merck to discover mAbs against undisclosed targets selected by Merck using OMT's OmniRats transgenic mAb platform

Open Monoclonal Technology Inc.

U.S. / Tools, Services, and Manufacturing

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Merck KGaA

Germany / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced